文献速递白血病

急性髓系白血病表观遗传靶向治疗的临床进展

Clinical developments in epigenetic-directed therapies in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

本文综述急性髓系白血病(AML)表观遗传修饰药物的临床开发进展。AML由获得性遗传和表观遗传异常驱动,但诱导治疗四十年來基本未变、多数患者预后不佳;随着对白血病表观基因组认识加深,多种表观遗传修饰剂进入不同阶段临床研究,本文从临床角度更新其治疗格局。

要点

  • AML由遗传与表观遗传异常共同驱动,多数患者预后仍不佳
  • 诱导治疗四十年來基本保持统一方案
  • 多种表观遗传修饰剂基于机制 rationale 进入临床开发各阶段

核心结论

  • 表观遗传修饰药物基于机制 rationale 进入临床开发,有望改善AML患者结局,本文对其治疗格局作临床导向的更新综述。

研究设计与样本

  • 综述类:检索范围与样本量原文未报告。

主要发现

  • AML为高度异质性疾病,源于获得性遗传与表观遗传异常,阻碍造血前体正常发育与分化。
  • 尽管生物学基础复杂多样,AML诱导治疗四十年來基本保持统一,多数患者结局仍不佳。
  • 对白血病表观基因组认识加深,促成多种表观遗传修饰剂的转化研究与临床开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a highly heterogeneous disease arising from acquired genetic and epigenetic aberrations which stifle normal development and differentiation of hematopoietic precursors. Despite the complex and varied biological underpinnings, induction therapy for AML has remained fairly uniform over 4 decades and outcomes remain poor for most patients. Recently, enhanced understanding of the leukemic epigenome has resulted in the translational investigation of a number of epigenetic modifying agents currently in various stages of clinical development. These novel therapies are based on mechanistic rationale and offer the potential to improve AML patient outcomes. In light of many recent advances in this field, we provide an updated, clinically oriented review of the evolving landscape of epigenetic modifying agents for the treatment of AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pan D, Rampal R, Mascarenhas J, et al. Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. Blood Adv. 2020. PMID: 32150613. doi:10.1182/bloodadvances.2019001245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。